undamentalytics Newsletter
Sign in

Tarsus Pharmaceuticals, Inc. income statement

In fiscal 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $451m, up 146.7% on the year before, operating income of −$71.0m (a -15.7% margin) and net income of −$66.4m, or −$1.59 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0572617183451606
Research and development19424350536488
Selling, general and administrative——45109237427526
General and administrative825—————
Operating income−27−12−63−143−121−71−49
Interest expense—023899
Income before tax−27−14−62−136−116−64—
Income tax00−0002—
Net income−27−14−62−136−116−66−46
Diluted EPS−$4.32−$0.67−$2.52−$4.62−$3.07−$1.59−$1.08
Diluted shares (average)6m21m25m29m38m42m43m
EBITDA−27−12−62−142−120−70−47

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MIRM vs TARSARWR vs TARSHCM vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tarsus Pharmaceuticals, Inc.